Amgen escapes lawsuit
Ariad Pharmaceuticals lost its appeals court bid to demand royalties from Amgen over the arthritis drug Enbrel, Bloomberg news reported. Enbrel is Thousand Oaks-based Amgen’s top-selling drug with sales of $758 million in the first quarter.
The U.S. Court of Appeals for the Federal Circuit in Washington said a lower-court judge was correct in his interpretation of certain aspects of the Ariad patent and in finding that Amgen doesn’t infringe the patent.
Are you a subscriber? If not, sign up today for a four-week FREE trial or subscribe and receive the 2009 Book of Lists free with your purchase.
